Search | Clinical Trials Finder

Conditions: Congenital Bleeding Disorder, Haemophilia B
Interventions: nonacog beta pegol; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 13 Years to 70 Years · Male only
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 13
States / cities: Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 10 more

Conditions: Hemophilia A
Interventions: SPK-8011, SPK-8016; Genetic
Lead sponsor: Spark Therapeutics, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2032
U.S. locations: 9
States / cities: Boston, Massachusetts • Madison, Mississippi • Kansas City, Missouri + 5 more

Conditions: Treatment of Bleeding, Prophylaxis of Bleeding, Hemophilia A, Children
Interventions: Damoctocog alfa pegol (Jivi, BAY94-9027); Biological
Lead sponsor: Bayer; Industry
Eligibility: 7 Years to 11 Years · Male only
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Congenital Bleeding Disorder, Haemophilia A
Interventions: turoctocog alfa; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 12 Years to 65 Years · Male only
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 18
States / cities: Little Rock, Arkansas • Long Beach, California • Tampa, Florida + 15 more

Conditions: Hemophilia A
Interventions: Desmopressin; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Severe Hemophilia A
Interventions: Emicizumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 0 Months to 12 Months
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2030
U.S. locations: 6
States / cities: Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 3 more

Conditions: Hemophilia, Menstrual Flow Excessive
Interventions: Recombinant FVIII Fc fusion product Eloctate, Recombinant FIX Fc fusion product Alprolix, Patient-operated diagnostic device for anemia AnemoCheck.; Drug · Device
Lead sponsor: Emory University; Other
Eligibility: 14 Years to 55 Years · Female only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Primary Immune Thrombocytopenia
Interventions: Rozanolixizumab; Drug
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hemophilia
Interventions: Fitusiran, Clotting factor concentrates (CFC) or bypassing agents (BPA), Antithrombin concentrate (ATIIIC); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 12 Years and older · Male only
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 8
States / cities: Orange, California • Minneapolis, Minnesota • Hackensack, New Jersey + 5 more

Conditions: Congenital Bleeding Disorder, Haemophilia A
Interventions: turoctocog alfa; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: Male only
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 6
States / cities: Mobile, Alabama • Torrance, California • Peoria, Illinois + 3 more

Conditions: Von Willebrand Disease (VWD), Von Willebrand Disease (VWD), Type 1, Von Willebrand Disease (VWD), Type 2, Von Willebrand Disease (VWD), Type 3
Interventions: HMB-002 (Part A), HMB-002 (Part B), HMB-002 with Concomitant Factor Concentrate (Part C) (Not Applicable in US); Drug
Lead sponsor: Hemab ApS; Industry
Eligibility: 16 Years to 69 Years
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 13
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 10 more

Conditions: Haemophilia A, Haemophilia B, Obesity
Interventions: No treatment given; Other
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 317 participants
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Plainsboro, New Jersey

Conditions: Hypofibrinogenemia, Hemorrhage, Trauma Associated Hemorrhage, Hemorrhagic Shock
Interventions: Pathogen Reduced Cryoprecipitated Fibrinogen Complex; Biological
Lead sponsor: Cerus Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 4
States / cities: Aurora, Colorado • Miami, Florida • Baltimore, Maryland + 1 more

Conditions: Myeloproliferative Disorder, Myeloproliferative Syndrome, Myelofibrosis, Polycythemia Vera, Essential Thrombocythemia
Interventions: USDA Diet, Mediterranean Diet; Other
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Irvine, California

Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions: cyclophosphamide, fludarabine phosphate, mycophenolate mofetil, tacrolimus, allogeneic bone marrow transplantation, radiation therapy; Drug · Procedure · Radiation
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 6 Months to 74 Years
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2015
U.S. locations: 3
States / cities: Atlanta, Georgia • Baltimore, Maryland • Philadelphia, Pennsylvania

Conditions: Hemophilia A
Interventions: ASC618; Biological
Lead sponsor: ASC Therapeutics; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Immune Thrombocytopenia
Interventions: Not listed
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 6 Months to 20 Years
Enrollment: 95 participants
Timeline: 2019 – 2023
U.S. locations: 6
States / cities: Aurora, Colorado • Boston, Massachusetts • New York, New York + 3 more

Conditions: Factor XIII Deficiency
Interventions: FXIII Concentrate (Human) (FXIII); Biological
Lead sponsor: CSL Behring; Industry
Eligibility: Not listed
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 25
States / cities: Dothan, Alabama • Oakland, California • Orange, California + 22 more

Conditions: Immune Thrombocytopenic Purpura (ITP)
Interventions: eltrombopag; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 2
States / cities: Nyack, New York • Cleveland, Ohio

Conditions: Hemophilia B
Interventions: Adeno-Associated Viral with Human Factor IX; Genetic
Lead sponsor: Avigen; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 3
States / cities: Palo Alto, California • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania

Conditions: Primary Immune Thrombocytopenia (ITP)
Interventions: Efgartigimod IV, Placebo IV; Biological · Other
Lead sponsor: argenx; Industry
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 18
States / cities: Phoenix, Arizona • Los Angeles, California • Oceanside, California + 15 more

Conditions: Severe Hemophilia A
Interventions: Factor VIII (rFVIIIFc), Advate®; Drug
Lead sponsor: Bioverativ Therapeutics Inc.; Industry
Eligibility: 12 Years and older · Male only
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 21
States / cities: Little Rock, Arkansas • Los Angeles, California • Orange, California + 17 more

Conditions: Wiskott-Aldrich Syndrome
Interventions: OTL-103; Genetic
Lead sponsor: Fondazione Telethon; Other
Eligibility: Up to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Hemophilia A
Interventions: Not listed
Lead sponsor: Emory University; Other
Eligibility: Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 7
States / cities: Aurora, Colorado • Atlanta, Georgia • Indianapolis, Indiana + 4 more

Search by objective public record fields.

Safety and Efficacy of NNC-0156-0000-0009 After Long-Term Exposure in Patients With Haemophilia B: An Extension to Trials NN7999-3747 and NN7999-3773

Long-Term Safety and Efficacy of Spark-Sponsored Gene Therapies in Males With Hemophilia A

A Study to Learn How Safe the Study Treatment BAY94-9027 is and How it Affects the Body in Previously Treated Children Aged 7 to Less Than 12 Years With Severe Hemophilia A, a Genetic Bleeding Disorder That is Caused by the Lack of a Protein Called Clotting Factor 8 (FVIII) in the Blood

Safety and Efficacy of Turoctocog Alfa in Haemophilia A Subjects

Characterization of Laboratory Response to DDAVP in Adult Hemophilia A Carriers

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Emicizumab in Participants From Birth to 12 Months of Age With Hemophilia A Without Inhibitors

Extended Half Life Factor (EHF) Products For Heavy Menstrual Bleeding in Hemophilia Carriers

A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)

A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia

Safety and Efficacy of Turoctocog Alfa During Long-Term Treatment of Severe and Moderately Severe Haemophilia A

A Study Assessing HMB-002 in Participants With Von Willebrand Disease

Awareness, Care, and Treatment In Obesity Management of Patients With Hemophilia (ACTION) to Inform Hemophilia Obesity Patient Empowerment (HOPE)

Cryo-FIRST: Effectiveness of INTERCEPT Fibrinogen Complex (IFC) for Trauma-Associated Hemorrhage

The NUTRIENT Trial (NUTRitional Intervention Among myEloproliferative Neoplasms): Feasibility Phase

Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer

ASC618 Gene Therapy in Hemophilia A Patients

Association of Platelet Parameters With Bleeding Severity in Children With ITP

An Open Enrollment Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency

A Study to Assess the Ability of Eltrombopag to Induce Sustained Response Off Treatment in Subjects With ITP

Safety of a New Type of Treatment Called Gene Transfer for the Treatment of Severe Hemophilia B

A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia

Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Subjects With Severe Hemophilia A

A Clinical Study to Evaluate the Use of a Cryopreserved Formulation of OTL-103 in Subjects With Wiskott-Aldrich Syndrome

Inhibitor Development in Patients With Hemophilia A Undergoing Surgery